LH(hCG) Receptor in Benign and Malignant Tumors of Human Ovary

Abstract

LH(hCG) receptors were identified with [1251]hCG in 38 benign and 26 malignant ovarian tumors of the human ovary. Eighteen per cent of all the benign and 27% of all the malignant tumors were LH(hCG) receptorpositive. Four of 12 benign serous tumors and 3 of 17 benign mucinous tumors dispIayed definitive binding of ['2SI]hCG. Two Brenner tumors failed to bind ['251]hCG. Six of 21 malignant epithelial tumors displayed definitive binding of ['2SI]hCG. Only one out of 4 malignant granulosa cell tumors bound [1251]hCG, while the pther sex cord stromal tumors as well as one dysgerminoma failed to bind ['251]hCG. LH(hCG) receptor content in the benign and malignant receptor-positive tumors was low compared with the normal ovarian tissue. The presence of LH(hCG) receptors in certain benign and malignant ovarian tumors may be a sign of the gonadotropic control of these tumors. The possible applications of these findings for the diagnosis and treatment of human ovarian tumors is discussed. Dysgerminoma 1 25 tropins in the development of ovarian tumors, the * Total number of patients 64 Acfo Obstet Gynecol Scond Suppl I01 84 H. Rajaniemi et al. * fmol/mg homogenate binding, n.d.b. =no definitive binding Receptor concentration in follicular cells on days 5 -6 is 0.82 10.25 fmol/mg homogenate protein and on day 13 1.36 10.34 fmol/mg homogenate protein. Acta Obstel Gyrrecol Scand Suppl 101 N.A. Dysgerminoma ovarii 25 n.d.b * f m o l h g homogenate protein, n.d.b. = no definitive binding Receptor concentration in follicular cells on days 5 -6 is 0.82k0.25 fmol/mg homogenate protein and on day 13 1.36k0.34 frnol/mg homogenate protein.

Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence

“…Human ovarian cancer cell lines were stimulated by gonadotrophins in vitro (Simon et al, 1983). Gonadotrophin receptors have been found in both benign and malignant ovarian tumours by several investigators (Kammerman et al, 1981;Rajaniemi et al, 1981), but not by others (Stouffer et al, 1984). In a case-control study women with PCO (polycystic ovary syndrome), had an increased risk of developing epithelial ovarian carcinoma (Schildkraut et al, 1996).…”

The Expression of hCG Receptor mRNA in Four Human Ovarian Cancer Cell Lines Varies Considerably under Different Experimental Conditions

“…Respective receptors have been detected immunohistochemically as well as on mRNA basis [7,[29][30][31][32][33]. The aim of our study was to evaluate whether the hCG receptor expression can be influenced chemically.…”

“…Receptor protein or mRNA has also been detected in various tumor tissues, including endometrial carcinomas [27], breast tumors [28], ovarian tumors [29][30][31][32][33][34], and three ovarian cancer cell lines (NIH:OVCAR-3, AO, and 3AO) [35,36], which means that these receptors can also be produced by cells of epithelial origin.…”

Influence of Human Luteinizing Hormone on Cell Growth and CA125 Secretion of Primary Epithelial Ovarian Carcinomas in vitro

“…Another rea son for the clinical benefit observed in pa tients treated with GnRH analogues could be a direct suppression of ovarian carcinoma cell growth mediated by membrane-bound GnRH receptors [9], Nonetheless, different in vitro studies investigating the direct influence of GnRH agonists on the growth of ovarian cancer cells in vitro gave conflicting results which could not explain therapeutic effects in clinical tumors definitively [10,11]. For sev eral years, any direct effect of gonadotropins on ovarian carcinomas was considered to be highly improbable since results of investiga tions studying the presence of gonadotropin receptors in ovarian cancer tissue were con troversial [12][13][14][15], In a recent study however, de Jong et al [16] were able to find receptors for human chorionic gonadotropin (hCG) which were mainly located in the neoplastic epithelium of malignant and benign ovarian tumors.…”